PE20030238A1 - Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales - Google Patents
Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronalesInfo
- Publication number
- PE20030238A1 PE20030238A1 PE2002000610A PE2002000610A PE20030238A1 PE 20030238 A1 PE20030238 A1 PE 20030238A1 PE 2002000610 A PE2002000610 A PE 2002000610A PE 2002000610 A PE2002000610 A PE 2002000610A PE 20030238 A1 PE20030238 A1 PE 20030238A1
- Authority
- PE
- Peru
- Prior art keywords
- spinal
- brain
- treatment
- trifluoromethyl
- benzyl
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title abstract 2
- 230000006378 damage Effects 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- JKHCSKNIYWXLNC-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-n-methylpyridine-3-carboxamide Chemical compound C=1N=CC=C(C=2C(=CC=CC=2)Cl)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JKHCSKNIYWXLNC-UHFFFAOYSA-N 0.000 abstract 1
- GTBUTLFXQOBLCG-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-methyl-4-(2-methylphenyl)pyridine-3-carboxamide Chemical compound C=1N=CC=C(C=2C(=CC=CC=2)C)C=1C(=O)N(C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GTBUTLFXQOBLCG-UHFFFAOYSA-N 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE ANTAGONISTA DEL RECEPTOR NK-1 DE FORMULA I DONDE R ES H, ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO; R1 ES H, HALOGENO; R Y R1 SON -CH=CH-CH=CH-; R2 Y R2' SON H, HALO, TRIFLUOROMETILO, ALQUILO, ALCOXILO, ENTRE OTROS; R2 Y R2' JUNTOS -CH=CH-CH=-CH- SUSTITUIDOS CON ALQUILO, HALO, ALCOXI; R3 ES H, ALQUILO, ENTRE OTROS; R4 ES H, -N(R5)2, -N(R5)(CH2)nOH, ENTRE OTROS; R5 ES H, CICLOALQUILO C3-C6, BENCILO, FENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-o-TOLIL-NICOTINAMIDA, N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-(2-CLORO-FENIL)-NICOTINAMIDA, N-(3,5-BIS-TRIFLUOROMETIL-BENCIL)-N-METIL-4-(2-TRIFLUOROFENIL)-NICOTINAMIDA, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR NK-1 Y SON UTILES PARA EL TRATAMIENTO DE LESIONES CEREBRALES, ESPINALES, NEURONALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01116812 | 2001-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030238A1 true PE20030238A1 (es) | 2003-03-19 |
Family
ID=8178001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000610A PE20030238A1 (es) | 2001-07-10 | 2002-07-08 | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20030083345A1 (es) |
| EP (2) | EP1406618A2 (es) |
| JP (1) | JP2004536119A (es) |
| KR (1) | KR100589106B1 (es) |
| CN (1) | CN100346789C (es) |
| AR (1) | AR037008A1 (es) |
| AU (1) | AU2002328837B2 (es) |
| BR (1) | BR0210893A (es) |
| CA (1) | CA2451566C (es) |
| GT (1) | GT200200143A (es) |
| HK (1) | HK1068266A1 (es) |
| HR (1) | HRP20031071A2 (es) |
| HU (1) | HUP0401210A3 (es) |
| IL (1) | IL159350A0 (es) |
| MX (1) | MXPA04000278A (es) |
| NO (1) | NO332847B1 (es) |
| NZ (1) | NZ530107A (es) |
| PA (1) | PA8549901A1 (es) |
| PE (1) | PE20030238A1 (es) |
| PL (1) | PL211246B1 (es) |
| RU (1) | RU2304435C2 (es) |
| UY (1) | UY27374A1 (es) |
| WO (1) | WO2003006016A2 (es) |
| ZA (1) | ZA200400138B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50932B (sr) * | 2000-07-14 | 2010-08-31 | F. Hoffmann-La Roche Ag. | N-oksidi kao prolekovi 4-fenil-piridinskih derivata koji su antagonisti nk1 receptora |
| NZ544244A (en) * | 2003-07-03 | 2008-10-31 | Hoffmann La Roche | Dual NK1/NK3 antagonists for treating schizophrenia |
| GB0410215D0 (en) * | 2004-05-07 | 2004-06-09 | Lescroart Pol | Nerve damage |
| JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎｋ−１受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
| US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
| CA2601935C (en) * | 2005-02-22 | 2013-04-09 | F. Hoffmann-La Roche Ag | Nk1 antagonists |
| KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| PL1863767T3 (pl) * | 2005-03-23 | 2009-08-31 | Helsinn Healthcare Sa | Metabolity antagonistów NK-1 do leczenia wymiotów |
| ES2439736T3 (es) | 2005-11-08 | 2014-01-24 | Vertex Pharmaceuticals Incorporated | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| DE102007018151A1 (de) * | 2007-04-16 | 2008-10-23 | Günenthal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| AU2008278273A1 (en) * | 2007-07-19 | 2009-01-22 | Adelaide Research & Innovation Pty Ltd | Method for reducing intracranial pressure |
| CN101910156B (zh) | 2007-12-07 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| CA2989620C (en) | 2007-12-07 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| EP2271622B1 (en) | 2008-02-28 | 2017-10-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR Modulators |
| GB0808747D0 (en) * | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| US20160129007A1 (en) * | 2013-07-02 | 2016-05-12 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for Preventing and/or Treating Chronic Traumatic Encephalopathy - IV |
| CA2914515C (en) * | 2013-07-02 | 2018-12-11 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-i |
| KR101903713B1 (ko) * | 2013-07-02 | 2018-10-04 | 유스트랄리스 파마슈티칼스 리미티드 (트레이딩 애즈 프레스수라 뉴로) | 만성 외상성 뇌병증-ii를 예방 및/또는 치료하는 방법 |
| KR20160078997A (ko) | 2013-11-08 | 2016-07-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 카복시메틸피페리딘 유도체 |
| US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
| JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
| CN111741755B (zh) * | 2018-02-02 | 2024-04-16 | 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） | 肠胃外制剂及其用途 |
| KR101970099B1 (ko) * | 2018-02-07 | 2019-04-17 | 한국과학기술연구원 | 척수 손상의 예방 및 치료용 조성물 |
| KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
| US20230124548A1 (en) * | 2019-08-23 | 2023-04-20 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Therapeutic Methods And Uses Thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
| IS4208A (is) * | 1993-09-22 | 1995-03-23 | Glaxo Group Limited | 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður |
| US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
| US5607947A (en) * | 1995-02-21 | 1997-03-04 | Eli Lilly And Company | Pyrrolidinyl tachykinin receptor antagonists |
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| TW382017B (en) * | 1995-12-27 | 2000-02-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives |
| CA2291734A1 (en) * | 1997-06-27 | 1999-01-07 | Merck Sharp & Dohme Limited | Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
| US5972938A (en) * | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
| DK1157005T3 (da) * | 1999-02-24 | 2005-02-14 | Hoffmann La Roche | 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister |
| ATE496032T1 (de) * | 1999-02-24 | 2011-02-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
| GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
| US6303790B1 (en) * | 1999-11-29 | 2001-10-16 | Hoffman-La Roche Inc. | Process for the preparation of pyridine derivatives |
| DE60006340T2 (de) * | 1999-11-29 | 2004-09-09 | F. Hoffmann-La Roche Ag | 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid |
| AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
-
2002
- 2002-07-02 US US10/187,587 patent/US20030083345A1/en not_active Abandoned
- 2002-07-03 KR KR1020047000395A patent/KR100589106B1/ko active IP Right Grant
- 2002-07-03 RU RU2004102397/15A patent/RU2304435C2/ru active
- 2002-07-03 CN CNB028135423A patent/CN100346789C/zh not_active Expired - Lifetime
- 2002-07-03 WO PCT/EP2002/007323 patent/WO2003006016A2/en active IP Right Grant
- 2002-07-03 CA CA2451566A patent/CA2451566C/en not_active Expired - Lifetime
- 2002-07-03 BR BR0210893-3A patent/BR0210893A/pt not_active IP Right Cessation
- 2002-07-03 EP EP02764617A patent/EP1406618A2/en not_active Withdrawn
- 2002-07-03 MX MXPA04000278A patent/MXPA04000278A/es active IP Right Grant
- 2002-07-03 NZ NZ530107A patent/NZ530107A/en unknown
- 2002-07-03 IL IL15935002A patent/IL159350A0/xx unknown
- 2002-07-03 EP EP05017203A patent/EP1621195A3/en not_active Withdrawn
- 2002-07-03 HU HU0401210A patent/HUP0401210A3/hu unknown
- 2002-07-03 JP JP2003511822A patent/JP2004536119A/ja active Pending
- 2002-07-03 PL PL369535A patent/PL211246B1/pl unknown
- 2002-07-03 AU AU2002328837A patent/AU2002328837B2/en not_active Expired
- 2002-07-05 PA PA20028549901A patent/PA8549901A1/es unknown
- 2002-07-08 PE PE2002000610A patent/PE20030238A1/es not_active Application Discontinuation
- 2002-07-08 AR ARP020102546A patent/AR037008A1/es unknown
- 2002-07-09 GT GT200200143A patent/GT200200143A/es unknown
- 2002-07-09 UY UY27374A patent/UY27374A1/es not_active Application Discontinuation
-
2003
- 2003-12-22 HR HR20031071A patent/HRP20031071A2/xx not_active Application Discontinuation
-
2004
- 2004-01-07 NO NO20040057A patent/NO332847B1/no not_active IP Right Cessation
- 2004-01-08 ZA ZA2004/00138A patent/ZA200400138B/en unknown
-
2005
- 2005-01-17 HK HK05100430A patent/HK1068266A1/xx not_active IP Right Cessation
-
2006
- 2006-07-05 US US11/481,216 patent/US20060247240A1/en not_active Abandoned
-
2010
- 2010-09-21 US US12/886,691 patent/US20110053954A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| PE20010009A1 (es) | Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1 | |
| PE20000170A1 (es) | Derivados benzosulfonas | |
| PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| AR021055A1 (es) | Derivados de pirazolopiridina | |
| PE20021094A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos | |
| PE20050598A1 (es) | Compuestos moduladores de cb1 | |
| PE20021072A1 (es) | DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2 | |
| PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
| HUP0402580A2 (hu) | 5-HT-antagonista tulajdonságú kinolinvegyületek és alkalmazásuk gyógyszerkészítmények előállítására | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20041061A1 (es) | Imidazol-4-il-etinil-piridina | |
| EA200300717A1 (ru) | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов | |
| TR200401546T4 (tr) | Piperazin türevleri, hazırlanmaları ve merkezi sinir sistemi (CNS) bozukluklarının tedavisinde kullanımları | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| NZ528997A (en) | Sulfonamides | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| EA200001114A3 (ru) | 2-(3,5-БИСТРИФТОРОМЕТИЛФЕНИЛ)-N-МЕТИЛ-N-(6-МОРФОЛИН-4-ИЛ-4-о-ТОЛИЛПИРИДИН-3-ИЛ)ИЗОБУТИРАМИД | |
| YU64901A (sh) | Derivati bifenila | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| EA200001184A1 (ru) | Фенилсульфонамидфенилэтиламины, полезные в качестве допаминовых рецепторов | |
| DK1254905T3 (da) | 4-(2-pyridyl)piperiziner med 5HT7 receptoragonistaktivitet | |
| PE20040172A1 (es) | Imidazolinilmetil aralquilsulfonamidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |